Clinical evaluation of a new laser-ablated titanium implant for bone-anchored hearing in 34 patients: 1-year experience 1 
| INTRODUCTION
Successful bone-anchored hearing implantation requires good osseointegration of the titanium implant in the temporal bone and low skin-related complication rates. The introduction of wider diameter implants, providing an enlarged bone-implant interface and thus a larger interface for osseointegration, has resulted in up to 3-year survival rates of >96% in healthy adult patients. [1] [2] [3] Despite the low incidence of implant loss in healthy adults, in certain patient groups, ie patients with compromised bone quality or in children, the incidence is much higher, varying between 3.5%-10.5% even with these wider diameter implants. [4] [5] [6] To improve implant survival in these populations as well, further optimisation of implant material, design and surgical technique remains needed.
Based on dental research, modifications of the implant surface, eg physical topography and chemical properties, could play a pivotal role in further optimising the integration in the recipient's bone. 7 As such, a new implant for bone conduction hearing was developed in 2015. This implant is, in contrast to currently used implants, selectively laser-ablated within the thread valley. Combined with modified chemical properties, this has shown improved biomechanical anchorage in pre-clinical animal testing. 8 In our clinical practice, before this implant is tested in patients with a higher risk of implant loss, it first has to be proven effective to use in healthy adults. This study, therefore, assesses retrospectively the performance of the new laser-ablated implant by reviewing implant survival, stability and soft tissue tolerability in healthy adults 1 year after surgery.
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| Ethical considerations
The ethics committee has passed a positive judgement on the study.
| Study population
The study was designed as a retrospective chart review approxi- To be included in the CMR-testing, patients had to be ≥18 years old and have no disease or treatment known to compromise the bone quality at the implant site. Exclusion criteria included inability to follow investigational procedure and any factor, at the discretion of the investigator, that was considered to contraindicate participation. As such, 34 healthy adult patients consented and received the laser-ablated implant between September 2015 and January 2016.
In all patients, a single-stage surgical procedure using a linear incision technique was performed under either local or general anaesthesia.
Subcutaneous soft tissue reduction during surgery was applied in one hospital, whilst subcutaneous soft tissue was preserved in the other two hospitals.
| Implant
The implant used was the wide Ponto BHX-implant (diameter, 4.5 mm; length, 3 or 4 mm)(Oticon Medical AB Askim, Sweden). This implant is, in contrast to traditional Br anemark type machined titanium implant surface, selectively laser-ablated within the thread valley to produce a microtopography with a superimposed nanotexture and a thickened surface oxide layer. Pre-mounted Ponto abutments of lengths 6, 9 and 12 mm were used, in case of tissue preservation depending on skin thickness measured during surgery.
| Follow-up evaluations and outcomes
Standard follow-up visits were performed 1 week, 4-6 weeks and approximately 1 year after implantation. An additional standard 3-month visit was performed in one of the 3 participating hospitals.
Implant survival and the degree of adverse skin reactions, according to the Holgers scale, 9 were noted at each visit. Holgers ≥2 were considered as adverse skin reactions, in which medical treatment 
| Comparisons with other studies
Implant survival and soft tissue tolerability seem comparable to the standard wide-diameter implants used in healthy adults. [1] [2] [3] However, due to the retrospective, multicentre nature of this study, using multiple surgical techniques, caution is needed in drawing conclusions especially regarding soft tissue tolerability. 
